Table 2.
Detection of CD markers in HC, CD, UC, IBS, subjects with anorexia
| Cohort | Number of samples | Detected | % detected | 95% CI* |
|---|---|---|---|---|
| Discovery cohort: IBD Spain | ||||
| HC* | 40 | 2 | 5 | 0.6 to 16.9 |
| HC-CD_Baseline* | 36 | 3 | 8.3 | 1.8 to 22.5 |
| HC-CD_3M* | 27 | 0 | 0 | 0 to 12.8 |
| HC-UC_Baseline* | 35 | 5 | 14.3 | 4.8 to 30.3 |
| HC-UC_3M* | 29 | 1 | 3.4 | 0.1 to 17.8 |
| CD-Baseline† | 34 | 27 | 79.4 | 62.1 to 91.3 |
| CD-3M† | 32 | 24 | 75 | 56.6 to 88.5 |
| CD-6M† | 27 | 22 | 81.5 | 61.9 to 93.7 |
| CD-9M† | 21 | 15 | 71.5 | 47.8 to 88.7 |
| CD-12M† | 21 | 17 | 81 | 58.1 to 94.6 |
| UC-Baseline* | 33 | 4 | 12.1 | 3.4 to 28.2 |
| UC-3M* | 26 | 2 | 7.7 | 0.9 to 25.1 |
| UC-6M* | 20 | 3 | 15.0 | 3.2 to 37.9 |
| UC-9M* | 17 | 2 | 11.8 | 1.5 to 36.4 |
| UC-12M* | 17 | 3 | 17.6 | 3.8 to 43.4 |
| Validation cohort | ||||
| CD Belgium | ||||
| CD-Baseline† | 54 | 39 | 72.2 | 58.4 to 83.5 |
| CD-1M-AS† | 44 | 37 | 84.1 | 69.9 to 93.4 |
| CD-3M-AS† | 42 | 35 | 83.3 | 68.6 to 93.0 |
| CD-6M-AS† | 47 | 42 | 89.4 | 76.9 to 96.5 |
| UC Spain | ||||
| UC* | 41 | 2 | 4.9 | 0.6 to 16.5 |
| IBS Spain | ||||
| IBS-Baseline* | 125 | 7 | 5.6 | 2.3 to 11.2 |
| IBS-3M* | 77 | 12 | 15.6 | 8.3 to 25.6 |
| IBD France‡ | ||||
| HC* | 38 | 2 | 5.3 | 0.6 to 17.7 |
| CD† | 146 | 88 | 60.3 | 51.9 to 68.3 |
| UC | 86 | 28 | 32.6 | 22.8 to 43.5 |
| Healthy UK | ||||
| HC | 1017 | 75 | 7.4 | 5.8 to 9.2 |
| Patients with anorexia | ||||
| AN | 158 | 9 | 5.6% | 2.6 to 10.5 |
*False positive (1-specifity).
†Sensitivity (true positive).
‡The authors of this previous work used a different region of the 16S rRNA gene (V3–V5 instead of V4; the other cohorts were analysed using V4) and a different sequencing platform (Ion Torrents).
12M, 12 months; 1M-AS, 1 month after surgery; 3M, 3 months; 3M-AS, 3 months after surgery; 6M, 6 months; 6M-AS, 6 months after surgery; 9M, 9 months; CD, Crohn's disease; HC, healthy controls; HC-CD, relatives of CD; HC-UC, relatives of UC.